Clinical Trial Update: Doxecitine and Doxribtimine-Expanded Access

View source ↗

Summary

Expanded access program for Doxecitine and Doxribtimine is available for Thymine Kinase 2 Deficiency, per sponsor UCB BIOSCIENCES, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thymine Kinase Deficiency

Drugs mentioned

• Doxecitine
• Doxribtimine

Snippet

Sponsor: UCB BIOSCIENCES, Inc. | Conditions: Thymine Kinase 2 Deficiency | Status: AVAILABLE